---
document_datetime: 2025-12-02 05:00:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/allex.html
document_name: allex.html
version: success
processing_time: 0.0430979
conversion_datetime: 2025-12-28 19:03:03.652303
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Allex

[RSS](/en/individual-human-medicine.xml/65671)

##### Withdrawn

This medicine's authorisation has been withdrawn

desloratadine Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 2 February 2004 the Marketing Authorisation Holder notified the European Commission of its decision to voluntarily withdraw the Markething Authorisation for Allex for commercial reasons. On 10 March 2004 the European Commission adopted the decision withdrawing the Marketing Authorisation for the medicinal product Allex.

## Product information

31/12/2009

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Allex Active substance desloratadine International non-proprietary name (INN) or common name desloratadine Therapeutic area (MeSH)

- Rhinitis, Allergic, Perennial
- Urticaria
- Rhinitis, Allergic, Seasonal

Anatomical therapeutic chemical (ATC) code R06AX27

### Pharmacotherapeutic group

Antihistamines for systemic use

### Therapeutic indication

Aerius is indicated for the relief of symptoms associated with:

- allergic rhinitis (see section 5.1)
- urticaria (see section 5.1)

## Authorisation details

EMA product number EMEA/H/C/000312 Marketing authorisation holder

Schering-Plough Europe

SP Europe

Marketing authorisation issued 15/01/2001 Withdrawal of marketing authorisation 10/03/2004

**This page was last updated on** 31/12/2009

## Share this page

[Back to top](#main-content)